Diversified Consumer Services
Company Overview of The Scripps Research Institute
The Scripps Research Institute is an educational institution that offers graduate programs and postdoctoral fellows in biological and chemical sciences. It also provides programs for high school and middle school students, teachers, and undergraduates. The institution was formerly known as Scripps Institutions of Medicine and Science. The Scripps Research Institute was founded in 1991 and is based in La Jolla, California.
10550 North Torrey Pines Road
La Jolla, CA 92037
Founded in 1991
Key Executives for The Scripps Research Institute
Executive Vice President and Chief Scientific Officer
Professor and Director of Neurological Research Center
Senior Director of Business Development
Compensation as of Fiscal Year 2014.
The Scripps Research Institute Key Developments
The Scripps Research Institute and T23 Announce Global Agreement
Jun 20 14
The Scripps Research Institute (TSRI) and T23 announced a global agreement for the development and commercialization of ligands for CD22, one of the family of siglecs (sialic acid-binding immunoglobulin-type lectins), discovered and characterized by TSRI Professor James Paulson. Siglecs modulate cellular signaling and immune system activation and inhibition. CD22 is found uniquely on B-cells. This licensing agreement will enable the proof-of-principal clinical development and commercialization of selective immune cell targeting and cellular modulation using siglec targets. This is an opportunity to develop more selective and effective treatments for B-cell neoplasms. Under the terms of the agreement, TSRI has granted to T23 exclusive worldwide rights to develop, manufacture, and commercialize certain complex formulations combining cytotoxins, siglec targeting ligands, and liposomal or other delivery systems. If successful, the new therapeutic would be an important new tool for treatment of a range of hematological tumors arising from B-cell lineages. In addition to the license, T23 will provide research support to the Paulson lab for three years. B-cell neoplasms cause about 4% of all cancers and nearly 90% of all lymphomas (hematological tumors). They exhibit a range of aggressiveness and have varying degrees of treatability. Survival rates also vary for different subtypes, however 5-year survival rates are about 70%. The targeted therapy, enabled using cd22-targeting of b-cell cancers, should extend survival and, more importantly, offer substantially higher cure rates than current therapies.
USC Might Acquire Scripps Research
Jun 17 14
Scripps Research Institute may merge or be acquired by the University of Southern California. USC and Scripps Research are discussing the possibility of a relationship that would enhance the missions of both institutions," the organizations said in a joint statement.
The Scripps Research Institute Announces Scripps Advance, New Drug Discovery Initiative
Apr 14 14
The Scripps Research Institute announced the formation of Scripps Advance, a new drug discovery initiative to translate early-stage biomedical research projects, both internal and external to TSRI, into clinical development candidates. Scripps Advance's first collaborator in this new endeavor is the Johnson & Johnson Innovation Center in California. Johnson & Johnson Innovation Center in California will tap into Scripps Advance's ties with academic researchers at TSRI, other academic centers and early stage companies to help identify potential collaborators. As part of the relationship, Advance will facilitate match-making between Johnson & Johnson Innovation and emerging life science companies, companies-in-planning, researchers conducting translational research and entrepreneurs that are part of Scripps Advance's network. Scripps Advance has already been active in the biotech space, collaborating with Atlas Venture, an early stage investment firm, to launch a company called Padlock Therapeutics. Padlock discovers novel therapeutics targeting the protein arginine deiminases (PADs), an emerging class of enzymes with roles in autoimmunity and epigenetic control. Padlock's technology was developed in the laboratories of TSRI investigators Paul Thompson, Ph.D., and Kerri Mowen, Ph.D., in collaboration with the Scripps Florida's high-throughput screening facility.
Similar Private Companies By Industry
Recent Private Companies Transactions
July 10, 2014